BTK and pneumococcal pneumonia: The effect of ibrutinib on acute inflammatory responses during ceftriaxone-treated pneumococcal pneumonia was not as pronounced as in LTA-induced lung inflammation likely because ibrutinib treatment was started 24 h after induction of infection, thus well after the initiation of inflammatory processes in the lung and activation of Btk expressing cells.